Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Gross Profit (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Gross Profit for 10 consecutive years, with $158.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 17.64% year-over-year to $158.7 million, compared with a TTM value of $561.3 million through Dec 2025, up 18.08%, and an annual FY2025 reading of $561.3 million, up 18.08% over the prior year.
  • Gross Profit was $158.7 million for Q4 2025 at Amicus Therapeutics, up from $149.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $158.7 million in Q4 2025 and bottomed at $59.9 million in Q1 2021.
  • Average Gross Profit over 5 years is $98.0 million, with a median of $89.5 million recorded in 2023.
  • The sharpest move saw Gross Profit increased 0.6% in 2022, then skyrocketed 37.07% in 2024.
  • Year by year, Gross Profit stood at $74.3 million in 2021, then rose by 5.93% to $78.7 million in 2022, then surged by 31.82% to $103.8 million in 2023, then rose by 29.99% to $134.9 million in 2024, then increased by 17.64% to $158.7 million in 2025.
  • Business Quant data shows Gross Profit for FOLD at $158.7 million in Q4 2025, $149.6 million in Q3 2025, and $139.5 million in Q2 2025.